Oxazepam (Serax)

03/01/1982 - "Oxazepam is recommended in alcoholic cirrhotics because its plasma clearance does not seem to be significantly affected by liver disease. "
03/01/1981 - "Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg. Age and liver disease have a minimal influence on oxazepam kinetics, but renal disease is associated with a prolonged half-life and increased volume of distribution. "
11/01/1968 - "[The autonomic stabilization of patients with liver diseases using Adumbran]."
06/01/1990 - "The disposition of oral oxazepam was investigated in seven patients with decompensated cirrhosis and encephalopathy and in nine healthy individuals to further examine the hypothesis of preservation of glucuronidation in liver disease. "
06/01/1990 - "In patients with liver disease, the unbound clearance of oxazepam correlated significantly with antipyrine clearance (r = 0.88; p less than 0.05). "

11/25/2002 - "Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study."
11/25/2002 - "During the 6 week treatment phase Valerian extract LI 156 (Sedonium) 600 mg/die showed a comparable efficacy to 10 mg/die oxazepam in the therapy of non-organic insomnia."
11/25/2002 - "Patients aged 18 to 73 years and diagnosed with non-organic insomnia according to ICD-10 (F 51.0) were treated in a multicentre, double-blind, randomised parallel group comparison with either 600 mg/die valerian extract LI 156 (Sedonium) or 10 mg/die oxazepam taken for 6 weeks. "
02/01/1984 - "Oxazepam produced some rebound insomnia, consisting of about an hour's reduction of polysomnographically defined sleep, but without gross mood disturbance or the patients' awareness of sleep loss."
02/01/1984 - "Oxazepam and flurazepam were effective in improving some polysomnographically defined measures of nocturnal sleep in 14 patients with chronic insomnia; flurazepam produced substantial daytime sleepiness and oxazepam did not. "

06/01/1995 - "Clinical characteristics of the seizures are different from that classically described in untreated patients, with the seizures being closely related to the cessation of oxazepam rather than the cessation of alcohol."
06/01/1995 - "A consistent relationship between the seizures and the cessation of oxazepam was noted, with peak incidence occurring 12-48 hr after the last oxazepam dose. "
07/01/1989 - "The apparent sensitivity to oxazepam's anticonvulsant effect, as examined by its effect on PTZ-induced maximal seizure, was increased in old animals of both sexes in comparison to young ones. "
01/01/1987 - "Brain concentrations of oxazepam and receptor occupancies were determined for each strain of mouse, at two different time points (1.5 and 7.5 h after drug treatment), at which equivalent seizure thresholds were obtained by manipulating the starting dose of oxazepam. "
01/01/1987 - "The effects of a single dose of oxazepam on seizure threshold, receptor occupancy and brain oxazepam concentration were investigated at several time points after drug treatment in two inbred strains of mice (NIH and C3H/HE). "

10/01/2001 - "Passiflora extract and oxazepam were effective in the treatment of generalized anxiety disorder. "
10/01/2001 - "A double-blind randomized trial compared the efficacy of Passiflora incarnata extract with oxazepam in the treatment of generalized anxiety disorder. "
10/01/2001 - "The results suggest that Passiflora extract is an effective drug for the management of generalized anxiety disorder, and the low incidence of impairment of job performance with Passiflora extract compared to oxazepam is an advantage. "
01/01/1968 - "[Oxazepam in alcoholism, depression and anxiety neuroses. "
01/20/1990 - "[D,L-kavain in comparison with oxazepam in anxiety disorders. "

01/01/1993 - "A commercially available very low calorie product for the treatment of obesity resulted in a decrease in oxazepam clearance and a lack of co-factors as a consequence of the low calorie intake was explanatorily proposed. "
06/01/1983 - "The influence of obesity on the distribution or clearance of lorazepam and oxazepam, two benzodiazepines biotransformed by glucuronide conjugation, was studied in a series of obese subjects (mean weight 113 kg; mean percent IBW 179%) and healthy controls of normal body habitus matched for age and sex. "
06/01/1983 - "Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen."
05/01/1986 - "Drug conjugation uniformly increases as a function of bodyweight in obesity, with paracetamol (acetaminophen), lorazepam and oxazepam having been studied. "